Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients

Ali Amro; Yalei Chen; Renee Barry; Laura Susick; Jessica Bensenhaver; Erica Proctor; Lindsay Petersen; S. David Nathanson; Haythem Ali; Randa Loutfi; Dhananjay Chitale; Alyson Simonds; Marcia Kuklinski; Ko Un Park; Melissa Davis; Lisa A. Newman

doi:10.1111/tbj.13256

Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients

Ali Amro, Yalei Chen, Renee Barry, Laura Susick, Jessica Bensenhaver, Erica Proctor, Lindsay Petersen, S. David Nathanson, Haythem Ali, Randa Loutfi, Dhananjay Chitale, Alyson Simonds, Marcia Kuklinski, Ko Un Park, Melissa Davis, Lisa A. Newman

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

We evaluated 328 patients (34.8% African American [AA]; 65.2% White American [WA]) with hormone receptor-positive, HER2/neu-negative breast cancer. Mean age (60 years); mean tumor size (1.6 and 1.7 cm for AA and WA, respectively) were similar, and mean BMI was higher for AA (33 vs 29.8; P = 0.001). Recurrence score (RS) distribution was similar- 8.3% AA and 5.9% WA with high RS (≥31). No significant differences were observed in delivery of chemotherapy stratified by score. With median follow-up 27.2 months for AA and 33.4 months for WA, distant recurrence occurred in 1.0% and 1.6%, respectively (P = 1). Our results suggest comparable RS utility in AA and WA patients.

Original language	English (US)
Pages (from-to)	667-671
Number of pages	5
Journal	Breast Journal
Volume	25
Issue number	4
DOIs	https://doi.org/10.1111/tbj.13256
State	Published - Jul 1 2019
Externally published	Yes

Keywords

Oncotype DX
breast cancer
disparities

ASJC Scopus subject areas

Internal Medicine
Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/tbj.13256

Cite this

Amro, A., Chen, Y., Barry, R., Susick, L., Bensenhaver, J., Proctor, E., Petersen, L., Nathanson, S. D., Ali, H., Loutfi, R., Chitale, D., Simonds, A., Kuklinski, M., Park, K. U., Davis, M., & Newman, L. A. (2019). Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients. Breast Journal, 25(4), 667-671. https://doi.org/10.1111/tbj.13256

Amro, A, Chen, Y, Barry, R, Susick, L, Bensenhaver, J, Proctor, E, Petersen, L, Nathanson, SD, Ali, H, Loutfi, R, Chitale, D, Simonds, A, Kuklinski, M, Park, KU, Davis, M & Newman, LA 2019, 'Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients', Breast Journal, vol. 25, no. 4, pp. 667-671. https://doi.org/10.1111/tbj.13256

@article{1b4257f1fb90432da51fe6726cccac16,

title = "Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients",

abstract = "We evaluated 328 patients (34.8% African American [AA]; 65.2% White American [WA]) with hormone receptor-positive, HER2/neu-negative breast cancer. Mean age (60 years); mean tumor size (1.6 and 1.7 cm for AA and WA, respectively) were similar, and mean BMI was higher for AA (33 vs 29.8; P = 0.001). Recurrence score (RS) distribution was similar- 8.3% AA and 5.9% WA with high RS (≥31). No significant differences were observed in delivery of chemotherapy stratified by score. With median follow-up 27.2 months for AA and 33.4 months for WA, distant recurrence occurred in 1.0% and 1.6%, respectively (P = 1). Our results suggest comparable RS utility in AA and WA patients.",

keywords = "Oncotype DX, breast cancer, disparities",

author = "Ali Amro and Yalei Chen and Renee Barry and Laura Susick and Jessica Bensenhaver and Erica Proctor and Lindsay Petersen and Nathanson, {S. David} and Haythem Ali and Randa Loutfi and Dhananjay Chitale and Alyson Simonds and Marcia Kuklinski and Park, {Ko Un} and Melissa Davis and Newman, {Lisa A.}",

note = "Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2019",

month = jul,

day = "1",

doi = "10.1111/tbj.13256",

language = "English (US)",

volume = "25",

pages = "667--671",

journal = "Breast Journal",

issn = "1075-122X",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients

AU - Amro, Ali

AU - Chen, Yalei

AU - Barry, Renee

AU - Susick, Laura

AU - Bensenhaver, Jessica

AU - Proctor, Erica

AU - Petersen, Lindsay

AU - Nathanson, S. David

AU - Ali, Haythem

AU - Loutfi, Randa

AU - Chitale, Dhananjay

AU - Simonds, Alyson

AU - Kuklinski, Marcia

AU - Park, Ko Un

AU - Davis, Melissa

AU - Newman, Lisa A.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - We evaluated 328 patients (34.8% African American [AA]; 65.2% White American [WA]) with hormone receptor-positive, HER2/neu-negative breast cancer. Mean age (60 years); mean tumor size (1.6 and 1.7 cm for AA and WA, respectively) were similar, and mean BMI was higher for AA (33 vs 29.8; P = 0.001). Recurrence score (RS) distribution was similar- 8.3% AA and 5.9% WA with high RS (≥31). No significant differences were observed in delivery of chemotherapy stratified by score. With median follow-up 27.2 months for AA and 33.4 months for WA, distant recurrence occurred in 1.0% and 1.6%, respectively (P = 1). Our results suggest comparable RS utility in AA and WA patients.

AB - We evaluated 328 patients (34.8% African American [AA]; 65.2% White American [WA]) with hormone receptor-positive, HER2/neu-negative breast cancer. Mean age (60 years); mean tumor size (1.6 and 1.7 cm for AA and WA, respectively) were similar, and mean BMI was higher for AA (33 vs 29.8; P = 0.001). Recurrence score (RS) distribution was similar- 8.3% AA and 5.9% WA with high RS (≥31). No significant differences were observed in delivery of chemotherapy stratified by score. With median follow-up 27.2 months for AA and 33.4 months for WA, distant recurrence occurred in 1.0% and 1.6%, respectively (P = 1). Our results suggest comparable RS utility in AA and WA patients.

KW - Oncotype DX

KW - breast cancer

KW - disparities

UR - http://www.scopus.com/inward/record.url?scp=85064808285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064808285&partnerID=8YFLogxK

U2 - 10.1111/tbj.13256

DO - 10.1111/tbj.13256

M3 - Article

C2 - 31025467

AN - SCOPUS:85064808285

SN - 1075-122X

VL - 25

SP - 667

EP - 671

JO - Breast Journal

JF - Breast Journal

IS - 4

ER -

Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this